TITLE
Anti-IL-17 monclonal antibody ixekizumab effect on chronic psoriasis

SUMMARY
Analysis of psoriatic skin biopsies from patients treated with 150mg of subcutaneous anti-IL-17 mAb ixekizumab (previously LY2439821) at weeks 0 and 2. IL-17 blockade resulted in a high-grade clinical improvement in psoriasis. Results provide insight into the role of IL-17 in disease pathogenesis.

ORGANISM
Homo sapiens

